Skip to main content

Postpartum Depression

After a Breakthrough Therapy guidance meeting with the US Food & Drug Administration (FDA), Sage Therapeutics announced plans to launch 3 additional studies of its investigational drug zuranolone.
Sage Therapeutics Inc's oral treatment for postpartum depression met the main goal of reducing symptoms of the condition, when compared with a placebo in a phase 3 clinical trial.
The benefits of Sage Therapeutics Inc's experimental treatment for postpartum depression outweigh risks, an advisory panel to the U.S. Food and Drug Administration said.
ORLANDO, Fla.—Infusion with the investigational compound brexanolone outperformed selective serotonin reuptake inhibitors (SSRIs) for the treatment of postpartum depression, according to a study presented at Psych Congress 2018.
Women who have asthma during their pregnancies are more likely to experience postpartum depression after delivery, a large Canadian study suggests.
Back to Top